Problem

Reticular addresses a high-stakes information gap in fertility care: IVF patients may have embryo data, but standard embryo testing primarily reports chromosomal abnormalities and does not provide the broader picture of inherited disease or pregnancy-loss risk. Reticular’s current site frames the problem as making embryo selection less blind by analyzing existing PGT data across additional health conditions and traits. The pain is both emotional and economic: IVF is expensive, treatment decisions are consequential, and couples must often interpret complex genetic and clinical information under significant uncertainty.

The main use case is an IVF couple deciding how to compare embryos after genetic testing. Reticular also serves people trying to conceive or experiencing recurrent pregnancy loss who do not yet have embryos, using an at-home partner saliva test to screen reproductive genes. Alongside the genetic service, the company targets the practical burden of IVF—scattered appointments, medication schedules, lab results, clinic paperwork, and costs—that can make an already stressful process harder to manage.

Product / Service

Reticular delivers a consumer-facing embryo and reproductive-genetics service. Customers can begin with existing embryo data or purchase an at-home partner screening kit; Reticular analyzes the genomic information, reports risk across reproductive and broader health conditions, compares embryos across traits, and provides genetic counseling to explain the results in plain language. The site lists a $250 price for one partner and $500 for both for its infertility and pregnancy-loss panel, which covers 750-plus reproductive genes and does not require IVF or embryos.

Reticular also offers Reti, an iOS IVF companion app. Users can maintain a treatment timeline, track appointments, medications, hormone and embryo results, symptoms, mood, and costs, while AI extracts structured information from uploaded clinic PDFs, transcribes voice input, and answers questions about the journey. The app is free to try with premium features, including more advanced AI models, priced at $4.99 per month in the App Store; it is positioned as an organizational and explanatory tool rather than a substitute for medical advice.

Market

Reticular competes at the intersection of reproductive health, consumer fertility software, genomic testing, and AI-assisted embryo assessment. In embryo polygenic screening, the closest named comparables are Genomic Prediction and Orchid, while Herasight is another company offering genetic-risk-based embryo screening. In IVF organization and patient support, relevant alternatives include Berry Fertility, Alife Health, Bonzun IVF, and Glow; Alife also competes more directly in AI-assisted embryo selection and received the first reported FDA clearance for an AI-powered embryo-selection tool in 2026.

The company appears to be in early commercialization rather than demonstrably scaled. Its current site says Reti is available on iOS and claims that thousands of people use it, but the App Store listing shows only four ratings, so independently verifiable user traction remains limited. Reticular has visible monetization through genetic-test kits and the paid app tier, and PitchBook reports $500,000 raised from investors including Y Combinator; YC lists the company as a Fall 2024, active, two-person San Francisco startup. No reliable public revenue figure is established in the available evidence.